Macula Lutea
Corpus Luteum
Acoustic Maculae
Juxtaglomerular Apparatus
Kidney Tubules, Distal
Sarcina
Progesterone
Luteolysis
Estrus
Ovary
Corpus Luteum Maintenance
Pseudopregnancy
Gentiana
Dinoprost
Luteal Cells
Saccule and Utricle
Ovarian Follicle
Tomography, Optical Coherence
Macular Degeneration
Pregnancy, Animal
Luteal Phase
Fluorescein Angiography
Estrous Cycle
Loop of Henle
Bruch Membrane
Chorionic Gonadotropin
Pregnancy
Luteinizing Hormone
Visual Acuity
Retinal Drusen
Prostaglandins F
Fundus Oculi
20-alpha-Dihydroprogesterone
Kidney Tubules
Lutein
Furosemide
Kidney Glomerulus
Gonadotropins, Equine
Diestrus
Sheep
Hair Cells, Vestibular
Sodium-Potassium-Chloride Symporters
Superovulation
20-Hydroxysteroid Dehydrogenases
Feedback
Solute Carrier Family 12, Member 1
Fovea Centralis
Choroid
Anestrus
Nitric Oxide Synthase Type I
Retinal Detachment
Estradiol
Feedback, Physiological
Retina
Arterioles
Relaxin
Rabbits
Granulosa Cells
Swine
Receptors, LH
Ear, Inner
Pigment Epithelium of Eye
Cattle
20-alpha-Hydroxysteroid Dehydrogenase
Theca Cells
Cloprostenol
Otolithic Membrane
Oxytocin
Kidney Cortex
Uterus
Cyclooxygenase 2
Pregnenediones
RNA, Messenger
Cholesterol Side-Chain Cleavage Enzyme
Immunohistochemistry
Retinal Pigment Epithelium
Prolactin
Proestrus
Choroid Diseases
Macular Edema
Bromocriptine
Histology, Comparative
Fertility
Progesterone Congeners
Perifoveal vascular leakage and macular oedema after intracapsular cataract extraction. (1/755)
Perifoveal capillary leakage of fluorescein was demonstrated in 60 per cent of 50 eyes when angiography was performed two weeks after cataract extraction. Repeat angiography six weeks postoperatively in 17 eyes demonstrated persistence of already established leakage in 11 of 12 eyes and no new leakage in five eyes previously negative. Cystoid macular oedema with visual acuity of less than 20/40 six weeks postoperatively occurred in five eyes (10 per cent). Eyes of patients with vascular disease and those patients of 60 years or older were found to have altered vascular permeability significantly more frequently. Inflammation was no more severe or prevalent in those patients who demonstrated leakage and no inflammation was clinically apparent in 10 of 11 eyes demonstrating dye leakage six weeks postoperatively. We conclude that the constitutional factors of age and vascular disease are of prime importance in causing altered vascular permeability in the early postoperative period after cataract extraction; factors causing sustained leakage with reduction of visual acuity were not demonstrated. (+info)The use of internal limiting membrane maculorrhexis in treatment of idiopathic macular holes. (2/755)
The purpose of this study was to assess surgical results of internal limiting membrane (ILM) maculorrhexis in macular hole surgery. This study is a part of continuing prospective clinical trial of our team of researchers. Thirteen eyes of 13 patients with idiopathic macular hole underwent vitrectomy with the removal of posterior cortical vitreous, peeling of the macular ILM, and intraocular gas tamponade, followed by postoperative face-down positioning. The excised specimens were evaluated with transmission electron microscopy. Complete closure of the hole was observed in all 13 eyes (100% anatomic success rate). Visual improvement of 2 or more lines on ETDRS visual acuity chart was achieved in 11 (85%) of the 13 eyes. Six (54.5%) eyes attained visual acuity of 20/50 or better. Electron microscopy showed ILM in the removed specimens. ILM maculorrhexis is a promising new surgical approach to close idiopathic macular holes but requires further investigation and long-term evaluation. (+info)Quantitative assessment of macular thickness in normal subjects and patients with diabetic retinopathy by scanning retinal thickness analyser. (3/755)
AIMS: To evaluate the scanning retinal thickness analyser (RTA), a novel non-invasive imaging instrument, in diagnosing and quantitatively characterising diabetic macular oedema, and to investigate the relation between central macula thickness measured by RTA and other clinical examinations. METHODS: Central macular thickness was measured using the RTA in 40 normal subjects and 60 patients with diabetic retinopathy. The reproducibility of the retinal thickness measurements was evaluated by calculating the mean of the inter- and intrasession variations. Central macular thickness was correlated with the results of visual acuity measurements, biomicroscopy, and fluorescein angiography. RESULTS: Intra- and intersession reproducibility of the RTA in normal subjects was plus or minus 5.2% (16 microns) and plus or minus 6.1% (19 microns), respectively. The mean central macular thickness was 182 (SD 16) microns in normal subjects, 283 (116) microns in diabetic eyes without clinically significant macular oedema (CSMO), and 564 (168) microns in diabetic eyes with CSMO. Central macular thickness was significantly greater (p < 0.001) in eyes with diabetic retinopathy than in normal subjects, even when macular thickening did not meet the standard for CSMO (p = 0.019) measured by biomicroscopy. Although greater fluorescein leakage at the macula results in greater central macular thickness, only eyes with diffuse leakage had statistically significant macular thickening compared with normal subjects (p = 0.022). Central macular thickness measured with the RTA was significantly correlated with the logarithmic converted visual acuity (r2 = 0.76) in diabetic eyes. CONCLUSION: Scanning RTA, which has good reproducibility, might be useful to quantitatively detect and monitor macular thickening in diabetic retinopathy. Central macular thickness was highly correlated with logarithmic converted visual acuity in diabetic macular oedema. (+info)Natural history of diabetic macular streak exudates: evidence from a screening programme. (4/755)
BACKGROUND/AIMS: Diabetic retinopathy screening guidelines recommend referral to an ophthalmologist if there is exudate within one disc diameter of the fovea. Many of these patients, however, have resolution of small amounts of exudate without treatment. This study aimed to assess whether patients with minimal streak or dot exudates within one disc diameter of the fovea can be monitored in a screening programme without compromising visual acuity. METHODS: A retrospective review of records and Polaroid photographs obtained by one screening centre over a 10 year period was performed. Outcomes measured were referral rates, alteration of Snellen visual acuity, and the need for macular photocoagulation treatment. RESULTS: 55 patients (74 eyes) fulfilled entry criteria (37 streak and 37 dot exudates). Mean follow up was 56.1 months (range 12-127 months). Twenty five patients (30 eyes) were referred to an ophthalmologist. 13 eyes (17.6%) required macular photocoagulation treatment. Four eyes (5.4%) lost two or more lines of Snellen acuity over the follow up period (three from macular oedema and one from macular ischaemia). There was no relation between the presence or resolution of minimal exudate and visual loss (p>0.2). CONCLUSION: It is appropriate to monitor eyes with streak or dot macular exudates at 6-9 monthly intervals in a screening programme. (+info)Macular vasculopathy and its evolution in incontinentia pigmenti. (5/755)
PURPOSE: To describe macular vasculopathy in incontinentia pigmenti. METHODS: Twelve baby girls with incontinentia pigmenti were examined under general anesthesia by fluorescein angiography of the macula. Nine eyes of 9 patients had sufficient detail to allow evaluation of capillary changes. Angiography was initiated as early as 3 months of age and was repeated in 7 eyes at 3- to 12-month intervals. Changes in capillary patterns were identified. RESULTS: Irregularly enlarged or distorted foveal avascular zones were noted in all 9 maculas. Sparseness of the perifoveolar capillary bed was a characteristic finding. Sequential macular angiography demonstrated non-progressive (stable) capillary closure in 2 eyes; progressive closure in another macula; progressive closure plus addition or reopening of macular capillaries in 3 eyes; and central retinal artery occlusion, with cherry-red spot formation, in 1 eye at 12 days of age. In addition, progressive tractional detachment of the macula occurred in 2 of these eyes, and progressive macular neovascularization occurred in 1 eye. CONCLUSIONS: Macular ischemia is characteristic of incontinentia pigmenti and is often progressive. It is the initiating event of a typical vasculopathy, characterized by capillary remodelling and, occasionally, by neovascularization and tractional detachment of the retina. (+info)The etiology and treatment of macular detachment associated with optic nerve pits and related anomalies. (6/755)
PURPOSE: Up to two thirds of patients with optic disc pits develop a sight-limiting maculopathy. There is confusion regarding the etiology and nature of the maculopathy in these cases. We present 7 cases of serous macular detachment occurring in association with optic pits or related cavitary anomalies and identify a rhegmatogenous etiology. METHODS: We reviewed the records of 7 patients with optic nerve anomalies and macular detachment. Patients were treated with observation, barricade laser, vitrectomy, and/or gas tamponade. RESULTS: Seven patients were noted to have serous macular detachment associated with an optic nerve pit or other cavitary anomaly. A hole or tear in the diaphanous tissue overlying the optic pit was identified in all cases. None of the patients had a posterior vitreous detachment. Two were treated with photocoagulation only, and 5 underwent pars plana vitrectomy with fluid-gas exchange with or without photocoagulation. Pretreatment visual acuity ranged from 20/30 to 6/200. Posttreatment acuity ranged from 20/25 to 20/100. Five of 7 eyes had final acuities of 20/30 or better, and all treated eyes improved. CONCLUSIONS: A tear in the diaphanous tissue overlying the optic nerve pit is responsible for the development of serous macular detachment and is consistent with findings in similar conditions, such as retinal detachment in association with chorioretinal coloboma. These tears may be quite subtle, and careful biomicroscopic examination is required to appreciate them. The treatment of this condition remains controversial. However, because of the relatively poor prognosis, we believe treatment should include the formation of a barricade to fluid movement as well as sealing and relief of traction from the hole. The value of laser treatment may be increased by the early identification of a defect in the diaphanous membrane prior to the development of macular detachment. Consideration of prophylactic laser might then reduce the need for later, more invasive measures, and improve the prognosis. (+info)The spectral sensitivity of the human short-wavelength sensitive cones derived from thresholds and color matches. (7/755)
We used two methods to estimate short-wave (S) cone spectral sensitivity. Firstly, we measured S-cone thresholds centrally and peripherally in five trichromats, and in three blue-cone monochromats, who lack functioning middle-wave (M) and long-wave (L) cones. Secondly, we analyzed standard color-matching data. Both methods yielded equivalent results, on the basis of which we propose new S-cone spectral sensitivity functions. At short and middle-wavelengths, our measurements are consistent with the color matching data of Stiles and Burch (1955, Optica Acta, 2, 168-181; 1959, Optica Acta, 6, 1-26), and other psychophysically measured functions, such as pi 3 (Stiles, 1953, Coloquio sobre problemas opticos de la vision, 1, 65-103). At longer wavelengths, S-cone sensitivity has previously been over-estimated. (+info)A practical method for measuring macular pigment optical density. (8/755)
PURPOSE: Increasing evidence indicates that the macular pigments (MP) protect the central retina and may retard macular disease. For that reason, a practical method for measuring MP that does not require elaborate optics and can be applied to diverse populations by operators with a modest amount of experience was developed and validated. METHODS: A small tabletop device based on light-emitting diodes (LEDs) as the light source with electronic controls was constructed. Macular pigment was measured with the tabletop device with a 1 degrees test stimulus at 460 nm using heterochromatic flicker photometry, and the results were compared with measurements using a traditional three-channel Maxwellian view system with a xenon-arc source. RESULTS: Macular pigment density of 30 subjects (age range, 16-60 years) was measured with both stimulus systems. Macular pigment measured with the LED tabletop device in free view was highly correlated with MP measured in Maxwellian view (y = -0.03 + 1.06x, r = +0.95). The average absolute difference between the two techniques was 0.04 (SD, 0.03). The new technique was not significantly affected by variations in lens optical density, pupil size, or small head movements. CONCLUSIONS: Psychophysical measurement of MP provides a unique opportunity to make repeated noninvasive assessment of the concentration of a protective nutrient in the retina. The availability of this new device should make this measurement technology accessible to a wide variety of investigators for application to diverse populations. (+info)There are two main types of MD:
1. Dry Macular Degeneration (DMD): This is the most common form of MD, accounting for about 90% of cases. It is caused by the gradual accumulation of waste material in the macula, which can lead to cell death and vision loss over time.
2. Wet Macular Degeneration (WMD): This type of MD is less common but more aggressive, accounting for about 10% of cases. It occurs when new blood vessels grow underneath the retina, leaking fluid and causing damage to the macula. This can lead to rapid vision loss if left untreated.
The symptoms of MD can vary depending on the severity and type of the condition. Common symptoms include:
* Blurred vision
* Distorted vision (e.g., straight lines appearing wavy)
* Difficulty reading or recognizing faces
* Difficulty adjusting to bright light
* Blind spots in central vision
MD can have a significant impact on daily life, making it difficult to perform everyday tasks such as driving, reading, and recognizing faces.
There is currently no cure for MD, but there are several treatment options available to slow down the progression of the disease and manage its symptoms. These include:
* Anti-vascular endothelial growth factor (VEGF) injections: These medications can help prevent the growth of new blood vessels and reduce inflammation in the macula.
* Photodynamic therapy: This involves the use of a light-sensitive drug and low-intensity laser to damage and shrink the abnormal blood vessels in the macula.
* Vitamin supplements: Certain vitamins, such as vitamin C, E, and beta-carotene, have been shown to slow down the progression of MD.
* Laser surgery: This can be used to reduce the number of abnormal blood vessels in the macula and improve vision.
It is important for individuals with MD to receive regular monitoring and treatment from an eye care professional to manage their condition and prevent complications.
Examples of retinal diseases include:
1. Age-related macular degeneration (AMD): a leading cause of vision loss in people over the age of 50, AMD affects the macula, the part of the retina responsible for central vision.
2. Diabetic retinopathy (DR): a complication of diabetes that damages blood vessels in the retina and can cause blindness.
3. Retinal detachment: a condition where the retina becomes separated from the underlying tissue, causing vision loss.
4. Macular edema: swelling of the macula that can cause vision loss.
5. Retinal vein occlusion (RVO): a blockage of the small veins in the retina that can cause vision loss.
6. Retinitis pigmentosa (RP): a group of inherited disorders that affect the retina and can cause progressive vision loss.
7. Leber congenital amaurosis (LCA): an inherited disorder that causes blindness or severe visual impairment at birth or in early childhood.
8. Stargardt disease: a rare inherited disorder that affects the retina and can cause progressive vision loss, usually starting in childhood.
9. Juvenile macular degeneration: a rare inherited disorder that causes vision loss in young adults.
10. Retinal dystrophy: a group of inherited disorders that affect the retina and can cause progressive vision loss.
Retinal diseases can be diagnosed with a comprehensive eye exam, which includes a visual acuity test, dilated eye exam, and imaging tests such as optical coherence tomography (OCT) or fluorescein angiography. Treatment options vary depending on the specific disease and can include medication, laser surgery, or vitrectomy.
It's important to note that many retinal diseases can be inherited, so if you have a family history of eye problems, it's important to discuss your risk factors with your eye doctor. Early detection and treatment can help preserve vision and improve quality of life for those affected by these diseases.
Retinal drusen appear as small, flat spots or patches in the retina and are usually yellow or orange in color. They are made up of lipids (fatty substances) and other waste products that have accumulated in the retina over time. The exact cause of retinal drusen is not known, but they are thought to be related to the natural aging process and the decline in the function of the retina over time.
Retinal drusen can be diagnosed with a comprehensive eye exam, which includes a visual acuity test, dilated eye exam, and imaging tests such as optical coherence tomography (OCT). There is no treatment for retinal drusen, but they can be monitored with regular eye exams to ensure that they are not progressing or causing any vision problems.
In some cases, retinal drusen may be a sign of a more serious underlying condition such as macular degeneration, which can cause vision loss if left untreated. It is important for individuals over the age of 50 to have regular comprehensive eye exams to detect any changes in the retina and to prevent vision loss.
In summary, retinal drusen are small deposits that accumulate in the retina and are a common age-related change. They do not cause vision problems on their own but can be an early warning sign of more serious eye diseases such as macular degeneration. Regular comprehensive eye exams can detect any changes in the retina and prevent vision loss.
The retina is a layer of cells that lines the inside of the eye and senses light to send visual signals to the brain. When the retina becomes detached, it can no longer function properly, leading to vision loss or distortion.
Retinal detachment can be caused by a variety of factors, including:
1. Age-related changes: As we age, the vitreous gel that fills the eye can become more liquid and pull away from the retina, causing a retinal detachment.
2. Injury or trauma: A blow to the head or a penetrating injury can cause a retinal detachment.
3. Medical conditions: Certain conditions, such as diabetes, high blood pressure, and sickle cell disease, can increase the risk of developing a retinal detachment.
4. Genetic factors: Some people may be more prone to developing a retinal detachment due to inherited genetic factors.
Symptoms of retinal detachment may include:
1. Flashes of light: People may see flashes of light in the peripheral vision.
2. Floaters: Specks or cobwebs may appear in the vision, particularly in the periphery.
3. Blurred vision: Blurred vision or distorted vision may occur as the retina becomes detached.
4. Loss of vision: In severe cases, a retinal detachment can cause a complete loss of vision in one eye.
If you experience any of these symptoms, it is important to seek medical attention immediately. A comprehensive eye exam can diagnose a retinal detachment and determine the appropriate treatment.
Treatment for retinal detachment typically involves surgery to reattach the retina to the underlying tissue. In some cases, laser surgery may be used to seal off any tears or holes in the retina that caused the detachment. In more severe cases, a scleral buckle or other device may be implanted to support the retina and prevent further detachment.
In addition to surgical treatment, there are some lifestyle changes you can make to help reduce your risk of developing a retinal detachment:
1. Quit smoking: Smoking has been linked to an increased risk of retinal detachment. Quitting smoking can help reduce this risk.
2. Maintain a healthy blood pressure: High blood pressure can increase the risk of retinal detachment. Monitoring and controlling your blood pressure can help reduce this risk.
3. Wear protective eyewear: If you participate in activities that could potentially cause eye injury, such as sports or working with hazardous materials, wearing protective eyewear can help reduce the risk of retinal detachment.
4. Get regular eye exams: Regular comprehensive eye exams can help detect any potential issues with the retina before they become serious problems.
Overall, a retinal detachment is a serious condition that requires prompt medical attention to prevent long-term vision loss. By understanding the causes and symptoms of retinal detachment, as well as making lifestyle changes to reduce your risk, you can help protect your vision and maintain good eye health.
Some common examples of choroid diseases include:
1. Choroidal neovascularization (CNV): This is a condition where new blood vessels grow under the retina, often as a result of age-related macular degeneration (AMD) or other eye conditions. These new vessels can cause vision loss and distortion.
2. Choroidal melanoma: This is a type of cancer that develops in the choroid layer of the eye. It is usually slow-growing, but it can spread to other parts of the body if left untreated.
3. Choroiditis: This is an inflammatory condition that affects the choroid layer of the eye, often as a result of infection or autoimmune disorders. It can cause vision loss and pain in the affected eye.
4. Choroidal rupture: This is a rare condition where the choroid layer of the eye ruptures, leading to bleeding and potentially severe vision loss.
5. Other conditions: There are several other conditions that can affect the choroid layer of the eye, such as choroidal vasculitis, choroidal effusion, and choroidal tumors. These conditions can cause a range of symptoms, including vision loss, pain, and distortion.
Overall, choroid diseases can have a significant impact on vision and eye health, and it is important to seek medical attention if any symptoms persist or worsen over time. Early detection and treatment can help to mitigate the risk of long-term vision loss and other complications.
Symptoms of macular edema may include blurred vision, distorted vision, blind spots, and sensitivity to light. Diagnosis is typically made through a comprehensive eye exam, including a visual acuity test and imaging tests such as optical coherence tomography (OCT).
Treatment for macular edema depends on the underlying cause of the condition. In some cases, medications such as anti-vascular endothelial growth factor (VEGF) injections or corticosteroids may be prescribed to reduce fluid buildup and swelling in the retina. In more severe cases, surgical intervention may be necessary, such as a vitrectomy to remove the vitreous gel and relieve pressure on the retina.
Prevention of macular edema includes managing underlying conditions such as diabetes and age-related macular degeneration, as well as maintaining regular eye exams to detect and treat any changes in the retina early on. Early detection and treatment can help prevent vision loss from macular edema.
History of Tay-Sachs disease
Tay-Sachs disease
Bananaquit
Macula of retina
Fovea centralis
Ludwig Laqueur
Retina
Haidinger's brush
Perifovea
Parafovea
Lutein
Xanthophyll
Meso-Zeaxanthin
Corpus luteum
Hermann Kuhnt
Friedrich August von Ammon
Foveola
List of MeSH codes (A09)
Otto Heinrich Enoch Becker
LMS color space
Layer of rods and cones
George Lindsay Johnson
Ophrys lutea
Amblypsilopus
Gibberula
Semiotus insignis
List of Sciapus species
Semiotus imperialis
List of distinct cell types in the adult human body
Stigma (anatomy)
List of data deficient arthropods
Aflibercept
List of data deficient insects
List of moths of North America (MONA 8322-11233)
Macula lutea: MedlinePlus Medical Encyclopedia
Genetic association of apolipoprotein E with age-related macular degeneration
DeCS 2018 - July 31, 2018 version
IndexCat
Advanced Search Results - Public Health Image Library(PHIL)
Ophthalmology Health Information | Mount Sinai - New York
A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular...
A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related...
മാക്യുല ലൂട്ടിയ - വിക്കിപീഡിയ
MeSH Browser
Definition of macroscopic - iDigitalPhoto Dictionary
Grant Abstract: Biochemistry and Pharmacology of the Macular Carotenoids
Subjects: Refractive Errors - Digital Collections - National Library of Medicine Search Results
DeCS
MeSH Browser
Pesquisa | BVS CLAP/SMR-OPAS/OMS
Estrogen Receptors
DeCS 2019 - June 12, 2019 version
Nerve fibers. Medical search. Definitions
NEW (2015) MESH HEADINGS WITH SCOPE NOTES
Search results | TNO Publications
MUSINA EBOBISSÉ QUARTET - Musina Ebobissé
Colour Perception
Cunningham's textbook of anatomy - Daniel John Cunningham - Google Livres
Health Psychology | The Department of Psychology
Anatomy of the Eye - Cut-away View : Medical Illustration
Parafovea
Anatomy Of Eye - Pharmacy Scope
Retina5
- Área oval de la retina, de 3 a 5 mm de diámetro, localizada usualmente en la zona temporal del polo posterior del ojo y ligeramente por debajo del nivel del disco óptico. (bvsalud.org)
- 2019), we employ the following definitions: foveal retina refers to a radius of 0.8 mm (5.5 diameter of visual angle), central retina refers to eccentricities up to 3.0 mm (first 10 radius of visual angle) where the ganglion cell layer is more than one cell thick, roughly equivalent to the diameter of the macula lutea (Boycott et al. (columbiagypsy.net)
- Parafovea or the parafoveal belt is a region in the retina that circumscribes the fovea and is part of the macula lutea . (iiab.me)
- Age Related Macular Degeneration is a common condition that affects the central part of the retina (the macula lutea) as people get older. (richardantcliff.com)
- They can be compared to sunglasses, as they filter short-wave light in the centre of the retina (macula lutea), providing a protective effect on the photoreceptors. (pro-macula.eu)
Fovea3
- The macula lutea, also called fovea, contains a very high concentration of cones. (medlineplus.gov)
- Retinas were free from any obvious pathology, and the yellow pigment of the macula lutea was readily distinguishable (which facilitated identification of the fovea before sectioning). (columbiagypsy.net)
- For example, he uses psychophysical methods to measure the concentration of the dietary carotenoids lutein and zeaxanthin within the fovea (termed macular pigment or the macula lutea) and have related those pigments to various aspects of retinal and brain function. (uga.edu)
Pigment2
- Abstract: The macular pigment carotenoids, lutein, zeaxanthin, and lutein's metabolite meso-zeaxanthin are uniquely concentrated in the primate foveal region to form the yellow pigment of the macula lutea where they can enhance visual function and protect against the light-induced oxidative damage that has been associated with age-related macular degeneration (AMD) and other disorders of the retina. (nih.gov)
- Lutein and zeaxanthin are carotenoids which are enriched in the macula and as an essential Pigment and which provide the yellow appearance. (pro-macula.eu)
Macular1
- To confirm the safety and compare the efficacy of intravitreal pegaptanib sodium 0.3 mg versus sham injections in subjects with diabetic macular edema (DME) involving the center of the macula associated with vision loss not due to ischemia. (nih.gov)
Light1
- When an eye is looking directly at an object, light rays from that object are focused on the macula lutea. (medlineplus.gov)
Structure1
- Abstract cal structure "Macula lutea structure" [SCTID:82859000]. (nih.gov)
Visual1
- Contiene en su centro a la fóvea central y aporta la mejor agudeza visual fototópica. (bvsalud.org)
Spot1
- A fundus photograph showing the macula as a spot to the left. (iiab.me)
Form1
- Very occasionally in the dry form the macula can wear out (atrophy). (richardantcliff.com)